Cytokine Signalling Forum

Publications




Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis

Strand V, van Vollenhoven R, Bong Lee E et al. - Strand et al. Rheumatology (Oxford). 2016 Feb 29. doi:pii: kev442. [Epub ahead of print]

RA not only affects the physical aspects of a patient’s health but also has an impact on the psychological well-being causing a significant disease burden. This paper reports on the patient-reported outcomes (PROs) from the ORAL Standard study.

This study investigated tofacitinib 5mg BID, 10mg BID, adalimumab vs. placebo over 12 months with a primary endpoint at month 3. All treatment groups showed significant improvements over placebo in HAQ-DI, PtGA and Pain with LSM changes in baseline sustained through month 12. It is also noted that greater proportions of patients in the tofacitinib and adalimumab reported ≥MCID in HAQ-DI, PtGA and Pain, with the greatest differences being reported in the tofacitinib groups (HAQ-DI in 5mg and PtGA and Pain in 10mg).

Both the tofacitinib and adalimumab treatment arms reported clinically meaningful improvements across a wider range of PROs. While improvements were achieved with both tofacitinib 5mg BID and adalimumab, the greatest improvements were observed with tofacitinib 10mg BID.

Access original article via Pubmed

Upload date: March 2016

Article image